Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Akari gains on Phase III PNH plans for C5 inhibitor

Brian Moy
September 21, 2017 11:53 PM UTC

Akari Therapeutics plc (NASDAQ:AKTX) gained $3.15 (56%) to $8.74 on Thursday after the company announced plans to start Phase III testing in 1Q18 of lead candidate Coversin to treat paroxysmal nocturnal hemoglobinuria.

The announcement appears to have removed an overhang that has weighed on Akari shares since spring, when Edison Investment Research Ltd. retracted a report titled “Akari’s Coversin matches Soliris in Phase II."...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Akari Therapeutics plc

Alexion Pharmaceuticals Inc.